MicroPort<sup>®</sup> Attends CCIF 2017

Hefei, China – From April 20 to April 22, Shanghai MicroPort Medical (Group) Co. Ltd. ("MicroPort®") attended the 20th China Cardiovascular Interventional Forum ("CCIF 2017") held in Hefei, Anhui Province and hosted a case contest. With over 4,000 cardiologists in attendance, the CCIF 2017 aims at promoting the new advancement of China's interventional cardiology and sharing the new philosophy, new technology and new method of interventional cardiology.
 
During the congress, the CCIF President Professor Yong Huo of Peking University First Hospital released the registration data of coronary heart disease interventional treatment in the Chinese mainland in 2016. According to the data, the total number of such treatment stood at 666,495, 17.4% up compared to 2015, and on average 1.5 stents were used in each case, which remained unchanged from the previous years. Professor Yaling Han of the General Hospital of Shenyang Military, who is also the academician of Chinese Academy of Engineering, introduced the China's Percutaneous Coronary Intervention ("PCI") Guide (2016) to the attendees. Professor Han said, based on the findings of the latest clinical studies and similar guides of ACC/AHA/ESC, this guide pays special attention to the China market as it includes the results of large-scale randomized clinical studies and clinical cases in China.
 
On April 22, MicroPort® hosted a case contest with 12 cases involved in. The first half of choosing "the most challenging case" was co-chaired by Professor Zuyi Yuan from the First Affiliated Hospital of Xi'an Jiaotong University, Professor Dadong Zhang of Shanghai Yodak Cardiothoracic Hospital, Professor Qiang Wu of Guizhou Provincial People's Hospital, and Professor An Bei of Qingdao Branch of Qilu Hospital of Shandong University, and the case of "emergency myocardial infarction associated with heart failure" by Minghui Wang of Tianjin Chest Hospital won the first place. The second half to select "the most educational case" was co-chaired by Professor Yongsheng Ke of the First Affiliated Hospital of Wannan Medical College, Professor Fucheng Sun of Beijing Hospital, and Professor Haiyan Wang of Tangdu Hospital of the Fourth Military Medical University, and the case of "a complex PCI" by Hongyu Peng of Beijing Anzhen Hospital of Capital Medical University took the crown. The venue was fully packed and the presentations were well received by the attendees who also had active interaction with the speakers.
 
Since 2016, MicroPort® hosted the case competition in various national-level congresses such as South China International Congress of Cardiology and Coronary Multidisciplinary & Interventional Therapeutics, and has received positive feedback. It was the second time for MicroPort® to host such seminar in the CCIF, which fully demonstrated the excellent performance of its stents in treating emergencies and complications and helped promote these products in the treatment of complex lesions. Lei Jiang, MicroPort® First Vice President of Domestic Coronary Sales & Marketing, said: "We hope to build an academic platform for experts of interventional treatment to discuss and share complex or typical cases, so as to promote the development of treatment technology in China's interventional cardiology and benefit more domestic patients."